Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Share-based Compensation of $6.4 million for Q1 2026, up 118.32% year-over-year from $2.9 million in Q1 2025, and up 18.37% quarter-over-quarter from $5.4 million in Q4 2025.
Oculis Holding AG (OCS) Share-based Compensation (2022 - 2026) Analysis & Trends
Oculis Holding AG's Share-based Compensation history runs 5 years deep, the most recent figure standing at $6.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 118.32% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $23.0 million (up 80.81% YoY), while the FY2025 annual figure was $19.4 million, up 74.03% from the prior year.
- Share-based Compensation for Q1 2026 stood at $6.4 million, up from $5.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $6.4 million in Q1 2026, with the low at $150513.2 in Q4 2022.
- The 5-year median for Share-based Compensation is $2.9 million (2024), against an average of $2.8 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation surged 733.86% in 2024, then soared 50.32% in 2025.
- Oculis Holding AG's Share-based Compensation stood at $150513.2 in 2022, then surged by 680.47% to $1.2 million in 2023, then soared by 176.17% to $3.2 million in 2024, then jumped by 66.3% to $5.4 million in 2025, then climbed by 18.37% to $6.4 million in 2026.
- Business Quant data shows OCS's Share-based Compensation at $6.4 million in Q1 2026, $5.4 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.39 Mn |
| Mar 31, 2026 | 6.39 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Dec 31, 2025 | 5.40 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Sep 30, 2025 | 5.70 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Jun 30, 2025 | 5.48 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Sep 30, 2024 | 2.89 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Jun 30, 2024 | 3.65 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Mar 31, 2024 | 1.31 Mn |
| Dec 31, 2023 | 1.17 Mn |
| Dec 31, 2023 | 1.17 Mn |